THE COMBINATION THERAPY OF ANTI-PD1 ANTIBODY PEMBROLIZUMAB AND ANTI-HER2 ANTIBODY TRASTUZUMAB EXERTS CARDIOTOXIC, PRO-INFLAMMATORY AND PRO-FIBROTIC PROPERTIES IN PRECLINICAL MODELS